Navigating the clinical to commercial transition for autologous therapies

The Pharma Letter, Andrea Zobel, Melissa Lattanzi and Jason Ramseth

Autologous cell therapies are some of the most innovative products being developed today, offering life-extending and potentially curative treatments for patients. Driven by increased investments and new regulatory guidance, officials anticipate a wave of new cell therapies by 20. In fact, there are more than 1,300 active cell therapy trials - which has grown significantly in recent years due, in part, to a dramatic increase CAR-T cell clinical trials. Cell therapies - most of which are of autologous origin - offer tremendous promise for patients worldwide, including who have conditions with few treatment options and no cures. However, the potential of these products could remain largely unrealized if innovators and their partners don’t develop a sound commercial strategy - one that accounts for the unique logistics considerations and end end solutions needed to support providers, payers and patients throughout the product journey.

For the full article, please visit The Pharma Letter.